Goldman Sachs
OLMA icon

Goldman Sachs’s Olema Pharmaceuticals OLMA Stock Holding History

Goldman Sachs’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-164,600
Closed -$2.45M – 6865
2026
Q1 		$2.45M Buy
+164,600
New +$3.66M ﹤0.01% 4359

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Goldman Sachs's OLMA Position: Q2 2026 in Review

Goldman Sachs increased its Olema Pharmaceuticals (OLMA) stake by 50% in Q2 2026, buying an estimated $7M and bringing the position to 1,567,979 shares worth $19.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

Goldman Sachs first reported a position in OLMA in Q4 2020 and has held it in 23 quarters since. The position peaked at $20.4M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Goldman Sachs held 1,567,979 shares of Olema Pharmaceuticals worth $19.6M as of Q2 2026.
  • Goldman Sachs bought 522,390 Olema Pharmaceuticals shares in Q2 2026, an estimated $7M.
  • Olema Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2645 holding.
  • Goldman Sachs first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Olema Pharmaceuticals position peaked at $20.4M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.